AR and breast carcinoma: In this study, we examined the effect of enzalutamide in AR + breast cancer models (ER + and ER–) and present the first preclinical evidence that inhibition of AR with enzalutamide may be an effective therapeutic strategy not only for ER–/AR + breast cancers, but also for ER+/AR + tumors.